Tcg Crossover Gp Ii, Llc Buys 4,271 Shares of Surrozen (NASDAQ:SRZN) Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Tcg Crossover Gp Ii, Llc purchased 4,271 shares of Surrozen stock in a transaction on Friday, January 30th. The shares were acquired at an average cost of $21.39 per share, with a total value of $91,356.69. Following the completion of the transaction, the insider directly owned 639,141 shares in the company, valued at $13,671,225.99. The trade was a 0.67% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Tcg Crossover Gp Ii, Llc also recently made the following trade(s):

• On Tuesday, February 3rd, Tcg Crossover Gp Ii, Llc acquired 4,355 shares of Surrozen stock. The shares were acquired at an average price of $21.94 per share, with a total value of $95,548.70.
• On Monday, February 2nd, Tcg Crossover Gp Ii, Llc acquired 731 shares of Surrozen stock. The stock was acquired at an average cost of $21.38 per share, for a total transaction of $15,628.78.

Surrozen Price Performance

NASDAQ:SRZN opened at $23.65 on Thursday. The company’s fifty day moving average price is $20.71 and its 200-day moving average price is $15.10. Surrozen, Inc. has a 1-year low of $5.90 and a 1-year high of $24.94. The firm has a market capitalization of $202.68 million, a P/E ratio of -1.06 and a beta of 0.58.

Surrozen (NASDAQ:SRZN) last posted its quarterly earnings results on Friday, November 7th. The company reported ($3.61) EPS for the quarter, missing the consensus estimate of ($1.17) by ($2.44). The business had revenue of $0.98 million during the quarter. Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. Equities analysts anticipate that Surrozen, Inc. will post -8.49 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Wall Street Zen raised Surrozen to a “sell” rating in a report on Friday, November 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Surrozen in a research note on Thursday, January 22nd. Finally, Lifesci Capital upgraded shares of Surrozen to a “strong-buy” rating in a research note on Thursday, November 13th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $32.00.

Institutional Trading of Surrozen

Institutional investors and hedge funds have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. raised its stake in shares of Surrozen by 50.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 1,500 shares of the company’s stock worth $34,000 after buying an additional 500 shares during the period. Citadel Advisors LLC grew its stake in Surrozen by 32.8% in the 3rd quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock valued at $179,000 after acquiring an additional 3,424 shares during the period. Geode Capital Management LLC grew its stake in Surrozen by 22.6% in the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after acquiring an additional 5,702 shares during the period. Armistice Capital LLC purchased a new stake in Surrozen in the 2nd quarter worth $536,000. Finally, Woodline Partners LP acquired a new position in Surrozen during the third quarter worth $621,000. 66.57% of the stock is currently owned by hedge funds and other institutional investors.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.